Gracell Biotechnologies Is A Clinical Stage Biopharmaceutical Company Based In Suzhouchinafocused On Developing Next Generation Cell Therapies For Cancers And Autoimmune Diseasesas Part Of The Astrazeneca Groupgracell Employs 314 People And Aims To Address Challenges In Car T Therapy Using Its Proprietary Technology Platforms The Companyae S Core Technologies Include Fastcarwhich Allows For The Rapid Manufacturing Of Autologous Car T Cellsand Truucarwhich Enables Allogeneic Car T Therapies Without The Need For Hla Matchinggracell S Pipeline Targets Hematological Malignancies And Solid Tumorswith Candidates Like Gc012F And Gc027As Well As Autoimmune Diseases Such As Systemic Lupus Erythematosusthe Company Emphasizes Manufacturing Speedcost Accessibilityand The Integration Of Crispr Cas9 Genome Editing In Its Development Processesgracell Has Multiple Candidates In Clinical Trials And Has Reported Pharmaceutical Sales In Chinasupported By Strategic Backing From Astrazeneca
